Iwona Sarzyńska-Długosz, Anna Szczepańska-Szerej, Artur Drużdż, Tomasz Łukomski, Stanisław Ochudło, Andrzej Fabian, Piotr Sobolewski, Katarzyna Mariańska, Joanna Maciejewska, Ewa Mulek, Alina Niedzielska, Romain Raymond, Magdalena M Brzózka, Maria Jessa-Jabłońska
AbobotulinumtoxinA (aboBoNT-A, Dysport®) is used in clinical practice as a well-tolerated and effective therapy for muscle spasticity. AboBoNT-A has been shown to reduce upper and lower limb spastic paresis in clinical trials, demonstrating improvements in muscle tone and limb function. This open-label, multicentre, observational, non-interventional study was the first to investigate aboBoNT-A's efficacy in adult patients with upper limb spasticity (ULS) in routine clinical practice in Poland. All enrolled patients received ≥1 aboBoNT-A injection cycles, per routine clinical practice (full analysis set, FAS), and ≥1 rehabilitation session...
January 20, 2020: Neurologia i Neurochirurgia Polska